Compliance with REMS Requirements in Spravato Billing

SPRAVATO^® (esketamine nasal spray) is a groundbreaking treatment for adults with treatment-resistant depression (TRD) and major depressive disorder. However, due to its potential risks, including sedation, dissociation, and abuse, the FDA mandates strict compliance with the Risk Evaluation and Mitigation Strategy (REMS) program.

To bill for Spravato correctly, healthcare settings and pharmacies need to be certified in the REMS program and follow all its requirements. This includes enrolling patients, administering under supervision, and monitoring them during treatment. Getting these steps right is key to both patient safety and proper reimbursement.

REMS for Spravato Billing

For Spravato, REMS is important because it is a controlled substance used in treating conditions like treatment-resistant depression.

Spravato has specific risks, including sedation, dissociation, and abuse potential, which is why it is only administered under strict supervision in a clinical setting. To mitigate these risks, the FDA has established REMS guidelines for healthcare providers to follow.

When it comes to billing for Spravato, REMS compliance is not just about following treatment protocols; it directly impacts the reimbursement process. Non-compliance can result in claim denials, delayed payments, or even audits, making it essential for medical billers to ensure that the REMS requirements are properly documented and followed.

4 Key REMS Requirements for Spravato

Before jumping into billing, let’s first review the essential REMS requirements that healthcare providers must follow when administering Spravato. These steps ensure that the treatment is given safely and that patients are properly monitored.

1. Patient Enrollment in REMS

Patients must be enrolled in the Spravato REMS program before receiving the treatment. This ensures that they understand the risks associated with Spravato, including potential side effects and the importance of being monitored during administration. The enrollment process involves:

• Informed Consent: Patients must sign an informed consent form, acknowledging the risks associated with Spravato and agreeing to the necessary monitoring.
• REMS Enrollment Confirmation: Medical professionals must confirm that the patient has been enrolled in the REMS program before administering the medication.

For medical billers, this means confirming that the necessary paperwork is completed and that the patient is enrolled in the REMS program. Without this documentation, billing may be delayed, and claims may be rejected.

2. Administration Under Supervision

Spravato can only be administered in a qualified healthcare setting, typically a medical office or clinic that is registered with the REMS program. The medication must be administered under the supervision of a healthcare provider due to the risk of sedation and other side effects.

Patients are required to remain under supervision for at least two hours after receiving the medication to monitor for any adverse reactions. Medical billers must ensure that the observation time is properly documented and billed accordingly, as this can affect reimbursement.

3. Providers Certification 

Healthcare providers administering Spravato must be certified under the REMS program, and they must renew their certification annually. This ensures that providers are properly trained to manage the risks associated with the treatment.

For billing purposes, it’s important to track the certification status of the healthcare provider, as reimbursement may be denied if the provider is not properly certified under the REMS program. Make sure to verify the provider’s certification before submitting claims.

4. Monitoring and Documentation of Adverse Effects

As part of REMS compliance, providers are required to monitor for adverse reactions after the administration of Spravato. Detailed documentation of these reactions must be maintained in the patient’s record. This includes:

• Monitoring for sedation, dissociation, or any other adverse effects.
• Patient vitals and any complications observed during the post-administration observation period.

This documentation must be complete and accurate, as it can be used to justify the medical necessity of the Spravato treatment and ensure compliance with REMS. Failure to provide this documentation can result in billing issues, including denied claims.

Billing Considerations for Spravato Under REMS

Now that we’ve covered the key REMS requirements, let’s dive into the specific steps for ensuring REMS compliance when billing for Spravato. By following these steps, you can ensure smooth claims processing and proper reimbursement.

1. Ensure Proper REMS Enrollment for Each Patient

Before administering Spravato, confirm that the patient is enrolled in the REMS program. This can be done by:

• Verifying the patient’s REMS enrollment through the Spravato REMS website or program portal.
• Documenting the patient’s informed consent in the patient’s record.
• Reviewing any restrictions that might apply to the patient based on their health status or previous treatments.

In your billing process, you’ll need to include proof of REMS enrollment as part of the patient’s medical record. This is important in case of an audit or review by insurance companies.

2. Use Appropriate Billing Codes

Proper coding ensures accurate reimbursement while avoiding claim denials due to non-compliance, making Spravato billing & coding critical. Commonly used Spravato billing codes are given below:

• HCPCS Code S0013: Esketamine nasal spray billed per 1 mg (for commercial insurance plans).
• G2082/G2083: Medicare-specific codes that include drug cost, administration, and monitoring services.
• ICD-10 diagnosis code: Along with the HCPCS code, ensure that the ICD-10 diagnosis code accurately reflects the patient’s condition. For example, use F33.2 for Major Depressive Disorder, Recurrent, and Severe (Treatment-Resistant Depression).
• Evaluation & Management (E/M) Codes:  For additional time spent on patient care, use codes 99202–99205 for new patients and 99212–99215 for established patients.

Use the appropriate billing codes based on the Spravato procurement model your practice follows.

3. Monitor and Document the Post-Administration Observation

After administering Spravato, the patient must remain under supervision for at least two hours. This period is crucial for monitoring for any adverse reactions, such as sedation, dissociation, or other side effects.

Ensure that the observation time is documented, and include this in the patient’s record for billing purposes.

If any adverse reactions occur, ensure that these are thoroughly documented. Insurance companies may require detailed reports about how the patient responded to Spravato during the observation period, so accurate records are critical for both patient safety and reimbursement.

4. Provider Certification and Compliance

Ensure that the healthcare provider administering Spravato is certified under the REMS program. This is an ongoing requirement, so it’s important to keep track of the provider’s certification status.

• Verify the provider’s certification annually to ensure they are up-to-date with the REMS guidelines.
• Document the provider’s certification in the patient’s file and your billing records. This can be useful if there’s a query from the insurance provider or a need to justify the provider’s qualifications.

5. Verify Insurance Coverage and Pre-Authorization

Before billing for Spravato, verify insurance coverage and pre-authorization requirements. Many insurance companies require pre-authorization for Spravato treatment, so it’s essential to confirm this before the medication is administered.

• Obtain pre-authorization when required, and submit this documentation with the claim.
• Verify the patient’s benefits to ensure that Spravato is covered under their plan, and check for any limitations or specific billing instructions.

6. Claims Submission

Once you’ve confirmed all the requirements; REMS enrollment, provider certification, observation time, and accurate coding, it’s time to submit the claim to the insurance provider. Ensure that the claim includes the following:

• Correct Usages of S0013, G2082 & G2083.
• Appropriate ICD-10 diagnosis codes for the condition being treated.
• Observation care billing codes if applicable.
• Proof of REMS enrollment and documentation of the post-administration monitoring.

By submitting a complete and accurate claim, you minimize the risk of claim denials and delays in reimbursement.

Common Billing Mistakes to Avoid in REMS Compliance for Spravato

Even experienced medical billers can sometimes make mistakes. Here are some common errors to watch out for:

1. Failure to Verify REMS Enrollment: Not confirming that the patient is enrolled in the REMS program can lead to claim rejections.
2. Missing Documentation of Observation Time: Ensure the post-administration observation period is fully documented, as it can impact reimbursement.
3. Incorrect Diagnosis Coding: Ensure that the diagnosis code matches the condition being treated and justifies the use of Spravato.
4. Not Checking Provider Certification: If the provider is not certified, the claim will be denied.
5. Skipping Pre-Authorization: Always verify pre-authorization requirements for Spravato and ensure that any necessary documents are submitted.

Conclusion

Compliance with the SPRAVATO^® REMS program is essential to ensure patient safety and meet FDA requirements. By certifying healthcare settings, enrolling patients properly, adhering to strict administration protocols, and maintaining accurate records, providers can deliver SPRAVATO^® treatments safely and effectively while avoiding compliance risks.